Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Rainard Fuhr"'
Autor:
Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1756-1768 (2021)
Abstract Safe and effective new oral therapies for autoimmune, allergic, and inflammatory conditions remain a significant therapeutic need. Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), and safety of the selective, covalent
Externí odkaz:
https://doaj.org/article/b831d07ed7124764bf42b3d566c92e8a
Autor:
Li-Ming Gan, Maria Lagerström-Fermér, Leif G. Carlsson, Cecilia Arfvidsson, Ann-Charlotte Egnell, Anna Rudvik, Magnus Kjaer, Anna Collén, James D. Thompson, John Joyal, Ligia Chialda, Thomas Koernicke, Rainard Fuhr, Kenneth R. Chien, Regina Fritsche-Danielson
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
Chemically modified mRNA is a new approach for therapeutic protein expression that could be applied to angiogenesis. Here the authors show in a phase 1 clinical trial that a modified mRNA encoding VEGF-A is well tolerated in patients with type 2 diab
Externí odkaz:
https://doaj.org/article/4edc38b69f3e4b73a58e9dddd556b69b
Autor:
Mary N. Brown, Rainard Fuhr, Jutta Beier, Hong-Lin Su, Yingxue Chen, Henrik Forsman, Ulrika Wählby Hamrén, Helen Jackson, Ajay Aggarwal
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-11 (2019)
Abstract Background Inhaled corticosteroids reduce inflammation in asthma but chronic use may cause adverse effects. AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, has the potential of an improved risk-benefit profile.
Externí odkaz:
https://doaj.org/article/701e52a7d84f496ab746e86d72a52734
Autor:
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Pim Gal, Gerd Mikus, Dietmar Trenk, Martin Coenen, Philippe Vieira Pires, Claudia Maschke, Antonios Othon Aliprantis, Nina Besche, Corina Becker
Publikováno v:
American Journal of Cardiovascular Drugs. 23:145-155
Autor:
Robert Wermers, Rainard Fuhr, Dirk Schnabel, Terra Arnason, Alix Bensacon, Borut Cizman, Deborah Wenkert, Yves Sabbagh, Kurt Gunter
Publikováno v:
Endocrine Abstracts.
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 60:269-279
To compare the pharmacokinetics (PK), pharmacodynamics (PD), safety, and immunogenicity between SB12 (a proposed eculizumab biosimilar) and the reference product (RP) eculizumab (i.e., European Union (EU)-sourced Soliris and United States (US)-source
Autor:
Arvind Kinhikar, Angela Sinn, Alessio Maiolica, Rainard Fuhr, Annamaria Jakab, Martin Kaul, Carole Schuhler, Magdalena Kistowska, Peter End, Maciej Cabanski, Bruno Cenni
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 5, Pp 1756-1768 (2021)
Clinical and Translational Science, Vol 14, Iss 5, Pp 1756-1768 (2021)
Safe and effective new oral therapies for autoimmune, allergic, and inflammatory conditions remain a significant therapeutic need. Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), and safety of the selective, covalent Bruton
Autor:
Christopher J. Delves, Caroline O. S. Savage, Tim S. Schmidt, Lea Fortunato, Emilie Charles, Thomas Matthew Webb, Lia Liefaard, Nicolas Wisniacki, John Stone, Rainard Fuhr, Sara Brett, Stephen A. Hughes, Ruth M. Tarzi, Muna Albayaty, Christine Barrett, Ken Edwards, Karen Leavens, Katherine Nevin, Rabia Anselm, Joanne Ellis, Shuo Tang, Martin Coenen, T.G. Hopkins, N Srinivasan, Yi Cui, Daniel J.B. Marks, Anna Richards, Maria Feeney
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1293-1303
Activated T cells drive a range of immune-mediated inflammatory diseases. LAG-3 is transiently expressed on recently activated CD4+ and CD8+ T cells. We describe the engineering and first-in-human clinical study (NCT02195349) of GSK2831781 (an afucos
Autor:
Mayank Singhal, Elina Turunen, Tuula Ahtola-Sätilä, John Aspegren, J. Raymond Bratty, Rainard Fuhr, Krista Ojala, Bert van Veen, Leena Peltonen
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 177
Particle size reduction leads to an increase in the drug dissolution rate, which in turn can lead to a substantial increase in the bioavailability of a poorly soluble compound. To improve bioavailability, a practically insoluble investigational drug,
Autor:
Rainard Fuhr, David Cook, John Ridden, Kerry Nield, Emma Leigh, Julie Cook, Heather Davies‐Strickleton, Juergen Dobmeyer
Publikováno v:
MycosesREFERENCES. 65(6)
BB2603 is a nano-formulation of the antifungal drug terbinafine with the polymer polyhexamethylene biguanide (PHMB) as an excipient to enhance solubility and drug delivery to skin and nails. BB2603 is delivered topically using a low-velocity spray. I